Adaptimmune Therapeutics Plc ADR (ADAP) saw an uptrend of 542127% in the recent trading with $1500000.0 being its most recent. The current price level -82.85% lower than the highest price of $1.48 marked by the stock while trading over the past 52-weeks, whereas it is 30.09% higher than the lowest price of $0.20 the company dropped to over past 52-weeks. The latest news story on ADAP appeared in (GuruFocus.com) under the title “Adaptimmune Therapeutics PLC (ADAP) Q1 2025 Earnings Call Highlights: Strong Tecelra Launch..” on May-14-25.
Do analysts rate it as a buy, sell or hold?
Irrespective of recent performance, what’s important is what the future holds. In uncertain economic times, a clear picture is difficult to get. Analysts generally have a good understanding of the market works, which gives them a leg up in making predictions. Currently, the stock has been recommended as Moderate Buy by 6 of the brokerage firms. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 2.25 for the stock.
Adaptimmune Therapeutics Plc ADR Earnings – What Happened With ADAP
Coming around sales and income figures on ADAP Stock Income Statement, public trading companies under normal circumstances post earnings and revenues near to average estimates by the Wall Street analysts, but those could came either above or below estimates and known as surprise factor.
Adaptimmune Therapeutics Plc ADR – Insider Activity and Holdings
Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). The total number of common shares currently owned by the public is 257.85 million. ADAP does have institutional investors; and they hold 34.07% of the stock.
As on 2024-06-30, MATRIX CAPITAL MANAGEMENT COMPANY, LP was the top most holder in Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) with an ownership of 38.97 million shares of the company or 2.5415 of the stake worth $38.0 million. The filing also reveals ECOR1 CAPITAL, LLC as the second largest holder in the company with a control over 1.787 of the outstanding shares. Its stake is worth $26.72 million for having 27.4 million shares in hand.
NEA MANAGEMENT COMPANY, LLC also came holding a key position in the company during the recent quarter and it now holds 1.1138 of the outstanding shares. With this there are now 85.0 institutions which have possession in ADAP’s shares.
Key Metrics forADAP
Technical Analysis of Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) stock
To comprehend better with the trade moves and investors’ behavior, exploring the short, medium and long term technical indicators along with average volume of a stock is an effective way to make use of. When looking into those indicators for Adaptimmune Therapeutics Plc ADR (ADAP), we notice that the stock’s 20-day average volume is at 616,395 shares and 100% of short term indicators are suggesting the stock as Sell. Medium term indicators at an average of 100% are spotting the stock at Sell with its 50-day average volume of 1,093,344 shares. And to end, ADAP’s 100-day average volume is 1,483,148 shares with 100% of the long-term indicators pointing towards Sell for the stock.
